SCINAI IMMUNOTHERAPEUTICS LTD.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.3M | $658.0K |
| Cost of Revenue | $4.0M | $1.2M |
| Gross Profit | $-2.7M | $-580.0K |
| Gross Margin | -202.3% | -88.1% |
| Operating Expenses | ||
| Research & Development | $2.4M | $5.5M |
| SG&A Expense | $2.5M | $2.5M |
| Operating Income | $-7.5M | $-8.6M |
| Operating Margin | -575.3% | -1,312.8% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-8.3M | $4.8M |
| Net Margin | -633.6% | 728.9% |
| EPS (Basic) | — | — |
| EPS (Diluted) | — | — |
| Shares Outstanding (Basic) | 9.34B | 9.68B |
| Shares Outstanding (Diluted) | 9.34B | 9.68B |
| Dividends Per Share | — | — |